Related Experiment Videos
Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCS
Abstract:
A randomized study comparing melphalan/prednisone (M/P) therapy with MP + natural alpha-IFN in untreated patients with multiple myeloma stages II and III started April 1, 1986. By March 1989, 78 patients were evaluable in the MP group and 80 in the MP/IFN group. 48% of the MP patients achieved a response and 66% in the MP/IFN group (p = 0.04). Stage II patients responded better to MP/IFN (76%) than MP alone (47%) (p = 0.02), while no statistically significant difference was noted for stage III patients. 90% of the IgA myelomas responded to MP/IFN and 52% to MP (p = 0.02). Both for IgG and BJ myelomas the response rates of MP/IFN were higher than of MP, although the differences were not statistically significant. The observation period is still short. There was no difference in total survival between the two treatment groups. However, in patients less than or equal to 65 years a tendency to a longer survival was seen for those receiving the IFN combination (p = 0.12).
Insights
Adding natural alpha-interferon (IFN) to melphalan/prednisone (MP) therapy improved response rates in multiple myeloma patients. Stage II and IgA myeloma patients showed significant benefits, with a trend towards longer survival in younger patients.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Multiple myeloma is a hematologic malignancy.
- Standard treatment often involves melphalan/prednisone (MP).
- Investigating novel therapeutic combinations is crucial for improving patient outcomes.
Purpose of the Study:
- To compare the efficacy of melphalan/prednisone (MP) therapy versus MP combined with natural alpha-interferon (IFN) in untreated multiple myeloma.
- To evaluate treatment response rates across different myeloma stages and subtypes.
Main Methods:
- A randomized study comparing MP therapy with MP + natural alpha-IFN.
- Inclusion criteria: untreated multiple myeloma, stages II and III.
- Patient evaluation for response rates and survival.
Main Results:
- Higher response rates observed in the MP + IFN group (66%) compared to the MP group (48%) (p=0.04).
- Stage II patients showed significantly better response to MP + IFN (76%) than MP alone (47%) (p=0.02).
- IgA myeloma subtype demonstrated a marked response difference: 90% for MP + IFN vs. 52% for MP (p=0.02).
Conclusions:
- Combination therapy with natural alpha-IFN enhances treatment response in multiple myeloma, particularly in Stage II and IgA subtypes.
- While overall survival showed no significant difference, a trend towards longer survival was noted in younger patients (≤65 years) receiving IFN.
- Further observation is warranted due to the short follow-up period.